Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of AP-325 in Subjects With Peripheral Post-surgical Neuropathic Pain

NCT04429919 is registered in ClinicalTrials.gov with Algiax Pharmaceuticals GmbH as lead sponsor.

NCT NCT04429919
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04429919 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of AP-325 in Subjects With Peripheral Post-surgical Neuropathic Pain
Lead sponsor
Algiax Pharmaceuticals GmbH
Phase
Phase 2
Overall status
Completed
Start date
June 22, 2020
Completion date
October 4, 2024
Enrollment
99 (actual)
Sites
32

Conditions

As the registry lists them; a condition with its own page is linked.

peripheral post-surgical neuropathic pain